Laura K Kline

US Patent:

7998507, Aug 16, 2011

Filed:

Dec 7, 2005

Appl. No.:

11/275069

Inventors:

H. William Bosch - Bryn Mawr PA, US
Greta G. Cary - Landsdale PA, US
Douglas C. Hovey - Gilbertsville PA, US
Rajeev A. Jain - Framingham MA, US
Laura J. Kline - Harleysville PA, US
Kevin D. Ostrander - Ringoes NJ, US
Niels P. Ryde - Malvern PA, US
Stephen B. Ruddy - Schwenksville PA, US

Assignee:

Elan Pharma International Ltd. - Athlone, County Westmeath

International Classification:

A61K 9/14
A61K 9/00
A61K 31/66
A61K 31/385
A61K 31/522
A61K 31/525
A61K 31/557
A61K 36/82
A61K 36/328
A61K 36/886
A61K 38/17
A61K 48/00

US Classification:

424489, 424729, 424744, 424748, 424768, 424776, 514 121, 514102, 514251, 51426331, 514440, 514561, 514573

Abstract:

Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

US Patent:

8512727, Aug 20, 2013

Filed:

Feb 24, 2004

Appl. No.:

10/784900

Inventors:

Eugene R. Cooper - Berwyn PA, US
Tuula Ryde - Malvern PA, US
John Pruitt - Collegeville PA, US
Laura Kline - Harleysville PA, US

Assignee:

Alkermes Pharma Ireland Limited - Dublin

International Classification:

A61F 13/00
A61K 9/14

US Classification:

424422, 424489

Abstract:

The present invention is directed to nanoparticulate compositions comprising meloxicam. The meloxicam particles of the composition have an effective average particle size of less than about 2000 nm.

US Patent:

20030181411, Sep 25, 2003

Filed:

Mar 20, 2003

Appl. No.:

10/392303

Inventors:

H. Bosch - Bryn Mawr PA, US
Greta Cary - Lansdale PA, US
Douglas Hovey - Trooper PA, US
Rajeev Jain - Collegeville PA, US
Laura Kline - Harleysville PA, US
Kevin Ostrander - Ringoes NJ, US

Assignee:

Elan Pharma International Ltd.

International Classification:

A61K048/00
A61K031/551

US Classification:

514/044000, 514/220000

Abstract:

Nanoparticulate compositions comprising at least one poorly soluble MAP kinase inhibitor and at least one surface stabilizer are described. The nanoparticulate compositions have an average particle size of less than about 2000 nm. The invention also describes methods of making and using such compositions.

US Patent:

20030232796, Dec 18, 2003

Filed:

Jun 10, 2003

Appl. No.:

10/457811

Inventors:

Eugene Cooper - Berwyn PA, US
Laura Kline - Harleysville PA, US
Gary Liversidge - West Chester PA, US
Niels Ryde - Malvern PA, US

Assignee:

Elan Pharma International, Ltd.

International Classification:

A61K031/56
A61K009/14

US Classification:

514/169000, 424/489000

Abstract:

The present invention is directed to nanoparticulate compositions comprising one or more polycosanols. The polycosanol particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of polycosanols and other cholesterol lowering agents are described and methods of using same are taught.

US Patent:

20040033202, Feb 19, 2004

Filed:

Jun 10, 2003

Appl. No.:

10/457787

Inventors:

Eugene Cooper - Berwyn PA, US
Laura Kline - Harleysville PA, US
Gary Liversidge - West Chester PA, US
Niels Ryde - Malvern PA, US

Assignee:

Elan Pharma International, Ltd.

International Classification:

A61K031/56
A61L009/04
A61K009/14

US Classification:

424/046000, 424/489000, 514/169000

Abstract:

The present invention is directed to nanoparticulate compositions comprising one or more sterols or stanols, such as sitosterol or phytosterol. The sterol particles of the composition have an effective average particle size of less than about 2000 nm. In another aspect of this invention, novel combinations of sterols and other cholesterol lowering agents are described and methods of using same are taught.

US Patent:

20040105778, Jun 3, 2004

Filed:

Sep 4, 2003

Appl. No.:

10/654600

Inventors:

Robert Lee - Boyertown PA, US
Matthew Hilborn - Spring City PA, US
Laura Kline - Harleysville PA, US
Janine Keller - Collegeville PA, US

Assignee:

Elan Pharma International Limited

International Classification:

A61L009/00
B01J019/00
A62B007/08
B01J019/08
A61L002/00

US Classification:

422/022000, 422/001000, 422/004000, 422/028000, 422/040000, 422/121000, 422/123000, 422/186000, 422/292000, 422/300000, 422/305000, 422/306000

Abstract:

The present invention relates to methods for terminal sterilization of solid forms of nanoparticulate active agent compositions via gamma irradiation. The nanoparticulate active agent has an effective average particle size of less than about 2 microns, prior to incorporation into a solid form for sterilization. The resultant sterilized compositions exhibit excellent redispersibility, homogeneity, and uniformity. Also encompassed are compositions made via the described method and methods of treating animals and humans using such compositions.

US Patent:

20040258757, Dec 23, 2004

Filed:

Jul 16, 2003

Appl. No.:

10/619539

Inventors:

H. Bosch - Bryn Mawr PA, US
Matthew Hilborn - King of Prussia PA, US
Douglas Hovey - Trooper PA, US
Laura Kline - Harleysville PA, US
Robert Lee - King of Prussia PA, US
John Pruitt - Collegeville PA, US
Niels Ryde - Malvern PA, US
Tuula Ryde - Malvern PA, US
Shuqian Xu - King of Prussia PA, US

Assignee:

Elan Pharma International, Ltd.

International Classification:

A61K009/14

US Classification:

424/489000

Abstract:

The present invention relates to liquid dosage compositions of stable nanoparticulate active agents. The liquid dosage compositions of the invention include osmotically active crystal growth inhibitors that stabilize the nanoparticulate active agents against crystal and particle size growth of the active agent.

US Patent:

20100143962, Jun 10, 2010

Filed:

Feb 11, 2010

Appl. No.:

12/704426

Inventors:

Eugene R. COOPER - Berwyn PA, US
Laura Kline - Harleysville PA, US
Gary G. Liversidge - West Chester PA, US
Niels P. Ryde - Malvern PA, US

International Classification:

C12N 5/078
C12M 3/00
C12M 3/06
C12Q 1/02

US Classification:

435 29, 4352891, 4352971, 435372

Abstract:

The invention provides a culture device comprising a plurality of culture units, wherein each unit comprises a culture chamber, an inlet port for liquid supply of the culture and an outlet port for discharging liquid from the unit, wherein the inlet port is in fluid communication with the culture chamber and the culture chamber is in fluid communication with the outlet port for allowing a liquid flow through the culture chamber. The culture device is particularly suitable for testing immune cells and immunofunction in vitro. Aspects of the invention include a culture device and associated methods for cultivating immune cells and an in vitro method of analysing the effect of a test compound on immune cells.